Location History:
- Riverdale, NY (US) (1997)
- Bayside, NY (US) (2004)
- Brooklyn, NY (US) (2006 - 2023)
Company Filing History:
Years Active: 1997-2023
Title: Jerome Owen Cantor: Innovator in Pharmaceutical Treatments
Introduction
Jerome Owen Cantor is a notable inventor based in Brooklyn, NY (US). He has made significant contributions to the field of pharmaceuticals, holding a total of 7 patents. His work primarily focuses on treatments for inflammatory disorders and related conditions.
Latest Patents
One of his latest patents is titled "Administration of N,N-dimethylacetamide for the treatment of preterm birth." This invention is directed towards treating inflammatory disorders through the administration of N,N-dimethylacetamide and its mono-methylated metabolites. The compounds developed are particularly useful in managing inflammatory disorders associated with preterm labor and premature rupture of membranes, which can lead to preterm birth. Another significant patent is "Compositions and methods for treating elastic fiber breakdown." This disclosure relates to pharmaceutical compositions that can regulate elastic fiber and methods for treating disorders related to elastic fiber breakdown, such as Chronic Obstructive Pulmonary Disease (COPD), through the inhalation of low-molecular weight hyaluronic acid.
Career Highlights
Throughout his career, Jerome has worked with various companies, including Matrx Therapeutics Corporation. His innovative approaches have led to advancements in pharmaceutical treatments, showcasing his dedication to improving healthcare outcomes.
Collaborations
Jerome has collaborated with notable individuals in his field, including Bronislava Shteyngart and Sandra Eve Reznik. These collaborations have further enriched his work and contributed to the development of his patents.
Conclusion
Jerome Owen Cantor's contributions to pharmaceutical innovations demonstrate his commitment to addressing critical health issues. His patents reflect a deep understanding of inflammatory disorders and the potential for new treatments.